In recent years, advances in the treatment of systemic lupus erythematosus (SLE) refractory to conventional therapy have been suggested in anecdotal series and some clinical trials. A number of promising agents have been studied only in murine models of SLE, and clinical trials are awaited. Rigorously conducted clinical trials must be completed to advance these studies to the point that new therapies for SLE will be approved.